Transition considerations for extended half-life factor products

Haemophilia

Volumn 21, Issue 3, 2015, Pages 285-288

  Croteau, S E ^a   Neufeld, E J ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT BLOOD CLOTTING FACTOR 8; RECOMBINANT BLOOD CLOTTING FACTOR 9; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9;

BLEEDING; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG HALF LIFE; DRUG INDICATION; DRUG INFUSION; DRUG LABELING; DRUG MARKETING; DRUG PACKAGING; EDITORIAL; HEMOPHILIA; HUMAN; PRESCRIPTION; PRIORITY JOURNAL; ECONOMICS; HALF LIFE TIME; HEMOPHILIA A; HEMOPHILIA B;

BLOOD COAGULATION FACTORS; FACTOR IX; FACTOR VIII; HALF-LIFE; HEMOPHILIA A; HEMOPHILIA B; HUMANS;

EID: 84928827020     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/hae.12683     Document Type: Editorial

References (8)

1. Mahlangu J, Powell JS, Ragni MV et al. Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A. Blood 2014; 123: 317-25.
2. Powell JS, Pasi KJ, Ragni MV et al. Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B. N Engl J Med 2013; 369: 2313-23.
3. Croteau SE, Saxena K, Neufeld EJ. Correlation between dispensed and prescribed doses of factor products for bleeding disorders: can a small, centre-based pharmacy hit the mark? Haemophilia 2015; 21: 190-5. doi: 10.1111/hae.12546.
4. Barnes C. Importance of pharmacokinetics in the management of hemophilia. Pediatr Blood Cancer 2013; 60(Suppl. 1): S27-9.
5. Berntorp E. Pharmacoeconomics of factor dosing in the haemophilia population. Haemophilia 2006; 12: 70-3.
6. Collins PW, Fischer K, Morfini M, Blanchette VS, Bjorkman S, International Prophylaxis Study Group Pharmacokinetics Expert Working G. Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophilia. Haemophilia 2011; 17: 2-10.
7. Collins PW. Personalized prophylaxis. Haemophilia 2012; 18(Suppl. 4): 131-5.
8. Xi M, Navarro-Ruan T, Mammen S et al. Systematic review of the published evidence on the pharmacokinetic characteristics of factor VIII and IX concentrates. 56th American Society of Hematology (ASH) Annual Meeting and Exposition. San Francisco, CA, 2014.